Dovitinib Shows Activity in Advanced Endometrial Cancer
the Cancer Therapy Advisor take:
Second-line dovitinib in FGFR2-mutated and FGFR2-non-mutated advanced or metastatic endometrial cancer had single-agent activity, but it did not reach the prespecified study criteria, a recent study published online first in the journal The Lancet Oncology.
For the non-randomized, two-group, two-stage, phase II trial, researchers enrolled 53 patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer whose disease had progressed after first-line chemotherapy. All women received dovitinib 500mg orally daily for 5 days and 2 days off until disease progression, unacceptable toxicity, study discontinuation, or death.
Results showed that the 18-week progression-free survival rates were 31.8% (95% CI: 13.9-54.9) in the FGFR2-mutated and 29.0% (95% CI: 14.2-48.0) FGFR2-non-mutated group.
In regard to safety, the most common serious adverse events associated with dovitinib use were pulmonary embolism, vomiting, dehydration, and diarrhea. One participant died due to treatment-related causes.
The findings suggest that efficacy of dovitinib is independent of FGFR2 mutation status. Additional studies are warranted to study the efficacy of dovitinib.
Second-line dovitinib in FGFR2-mutated and FGFR2-non-mutated advanced or metastatic endometrial cancer had single-agent activity.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?
- Olaratumab May Be Safe and Effective in Patients With Advanced Soft Tissue Sarcoma
- Next-Generation Sequencing May Benefit Some Patients With Sarcoma